Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114.44M | $102.25M | $120.99M | $116.74M | $102.69M | $87.12M | $95.64M | $76.87M |
| Cost of revenue | $36.20M | $34.04M | $36.72M | $32.22M | $31.79M | $28.64M | $29.44M | $29.05M |
| Gross profit | $78.24M | $68.21M | $84.27M | $84.53M | $70.90M | $58.48M | $66.21M | $47.83M |
| Gross margin | 68.4% | 66.7% | 69.6% | 72.4% | 69.0% | 67.1% | 69.2% | 62.2% |
| Research and development | $19.66M | $19.80M | $24.54M | $19.83M | $15.08M | $12.58M | $11.59M | $11.67M |
| Selling, general and administrative | $76.04M | $74.59M | $73.96M | $67.95M | $46.86M | $50.45M | $45.81M | $43.94M |
| Operating expenses | $95.69M | $125.68M | $98.50M | $87.78M | $61.94M | $63.03M | $57.40M | $55.61M |
| Operating income | −$17.46M | −$57.47M | −$14.24M | −$3.25M | $8.96M | −$4.55M | $8.81M | −$7.78M |
| Operating margin | -15.3% | -56.2% | -11.8% | -2.8% | 8.7% | -5.2% | 9.2% | -10.1% |
| EBITDA | −$10.74M | −$19.38M | −$7.35M | $3.22M | $15.15M | $1.13M | $14.36M | −$1.85M |
| Interest income | $0 | $0 | −$520.00K | −$562.00K | $0 | $0 | −$698.00K | −$843.00K |
| Interest expense | −$1.19M | −$717.00K | $0 | — | −$817.00K | −$640.00K | $0 | — |
| Income before taxes | −$18.26M | −$62.42M | −$18.23M | −$7.39M | $10.56M | −$6.08M | $5.41M | −$8.36M |
| Income taxes | −$518.00K | $897.00K | −$564.00K | $247.00K | −$246.00K | $447.00K | −$24.00K | −$47.00K |
| Net income | −$17.74M | −$63.32M | −$17.67M | −$7.64M | $10.81M | −$6.53M | $5.44M | −$8.31M |
| Net margin | -15.5% | -61.9% | -14.6% | -6.5% | 10.5% | -7.5% | 5.7% | -10.8% |
| EPS, basic | −$0.60 | −$2.16 | −$0.61 | −$0.27 | $0.38 | −$0.23 | $0.20 | −$0.31 |
| EPS, diluted | −$0.60 | −$2.16 | −$0.63 | −$0.27 | $0.36 | −$0.23 | $0.20 | −$0.31 |
| Diluted shares | 29.71M | 29.34M | 27.87M | 28.80M | 29.75M | 28.15M | 27.79M | 27.10M |
Figures describe GeneDx shares, not any token. As of Aug 3, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.